CliffBio
small molecule

HYDROMORPHONE HYDROCHLORIDE

HYDROMORPHONE HYDROCHLORIDE

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry
CompanyHikma →See this company's full patent-cliff portfolio

Drug detail

Brand nameHYDROMORPHONE HYDROCHLORIDE
Active ingredientHYDROMORPHONE HYDROCHLORIDE
Strength40MG/20ML (2MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalDecember 2023
Marketing statusRX

Listed patents

PatentExpiresType
12653820January 2043product

More from Hikma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.